Developing a Research Proposal

Diana Redwood, PhD, MPH



EPIDEMIOLOGY CENTER

Land Acknowledgement

Thank you to the Dena'ina people, on whose traditional lands I live. Thanks for their past and present stewardship of the waters, plants, animals and spiritual practices of this place.

What is a research proposal?

A <u>detailed description</u> of a proposed <u>research study</u> that you're designing to investigate a particular <u>problem</u>



Why would you write one?

- For your employer/university For IRB and tribal review
- For funding
- So you (and your team) know what you're doing
- So you can identify gaps in your research
- Your proposal may look a little different for each audience!

Case Study:

Randomized controlled trial of the stool DNA test to improve colorectal cancer screening among Alaska Native people (R01CA247642)

Select your topic



Colorectal cancer is the second most common cancer among AN people



...And the second leading cause of cancer death



Disparities in CRC incidence have persisted for over 40 years.



Source: Alaska Native 50 Year Report, Alaska Native Tumor Registry, 2021

Select your topic Perform a literature review



- Alaska Native people have among the highest rates of CRC in the world
- Due to the geographic and health care delivery challenges of CRC screening in Alaska, only around 68% of Alaska Native people have been adequately screened for CRC
- A new screening method, the stool DNA test, is now available, but hasn't been used in the Alaska Tribal Health System

Select your topic Perform a literature review

Gather your team



























Select your topic Perform a literature review

Gather your team PLAN PLAN PLAN



Elements of a research proposal

Title Abstract Introduction Problem statement Objectives **Hypothesis** Methods Sharing results

Title

Should be: Concise Descriptive Catchy Comprehensible



A randomized controlled trial of the stool DNA screening test using high and medium intensity patient navigation to improve colorectal cancer screening among Alaska Native people living in remote Alaskan communities

VS.

Randomized controlled trial of the stool DNA test to improve colorectal cancer screening among Alaska Native people

Abstract

Brief summary, ~300 words Summarize all the elements of the project Stand-alone Highlight the importance of the work Only 59% (29-73%) of Alaska Native people have been adequately screened for colorectal cancer (CRC), which could save lives, despite having the highest reported incidence of CRC in the world. A new at-home multi-target stool DNA screening test (MT-sDNA; Cologuard®) with high sensitivity for pre-cancerous polyps and CRC is now available. MT-sDNA has not been tested for feasibility or acceptability within the Alaska tribal health care delivery system and it is unknown whether use of this new test will increase Alaska Native CRC screening rates. Our long-

Problem Statement

C-attributable mortality. The objective of this application is to test screening in Alaska Native communities using a mixed methods,

community-based participatory research (CBPR) approach. The study will be conducted in collaboration with regional Tribal health organizations who are responsible for providing health care to geographically remote Alaska Native communities. This research has been requested by Tribal organizations. Although the proposed implementation strategy is evidence-informed and promising, it is novel in that MT-sDNA has not been evaluated in the tribal health setting or among rural/remote populations. Using the Social Ecological Model, our research will be multi-level, examining influence on patients, providers, and tribal health organizations (THOs). This research study will pursue two specific aims: (1) Identify patient-, provider-, and system-level factors associated with CRC screening preferences, uptake, and follow-up; and (2) test the effectiveness of graded intensity MTsDNA intervention in the Alaska Native community setting. For the first aim, focus groups with Alaska Native people who are non- or inadequately adherent to CRC screening guidelines, and surveys and interviews with healthcare providers will be used to identify individual, interpersonal (provider), and health system factors for future intervention. For the second aim, a three-arm cluster randomized controlled trial (high intensity with patient navigation, medium intensity with mailed reminders, usual care) will provide evidence on the usefulness of MTsDNA in remote tribal communities as well as the first data on MT-sDNA diagnostic follow up adherence rates in the Alaska Native population. This aim will also provide evidence on the usability of MT-sDNA in the Alaska setting by evaluating MT-sDNA sample quality and neoplastic yield, which will inform plans to scale-up the intervention model. This project is innovative because an effective strategy for achieving higher screening rates than current practice could lead to increased prevention or early detection of CRC cases among Alaska Native people. The proposed research is significant because it will address a health disparity of community concern. This research has the potential to sustainably improve public health by increasing CRC screening rates among a rural/remote

Only 59% (29-73%) of Alaska Native people have been adequately screened for colorectal cancer (CRC), which could save lives, despite having the highest reported incidence of CRC in the world. A new at-home multi-target stool DNA screening test (MT-sDNA; Cologuard®) with high sensitivity for pre-cancerous polyps and CRC is now available. MT-sDNA has not been tested for feasibility or acceptability within the Alaska tribal health care delivery system, and it is unknown whether use of this new test will increase Alaska Native CRC screening rates. Our long-term goal is to improve screening and reduce CRC-attributable mortality. The objective of this application is to test the effectiveness of MT-sDNA for increasing CRC screening in Alaska Native communities using a mixed methods, community-based participatory research (CBPR) approach. The study will be conducted in collaboration with regional Tribal health organizations who are responsible for providing health care to geographically remote Alaska Native communities. This research has been requested by Tribal organizations. Although the proposed implementation strategy is evidence-informed and promising, it is novel in that MT-sDNA has not been evaluated in the tribal health.

How this study will address the problem will be multi-level, IOs). This research study will pursue two specific aims: (1) Identify patient-, provider-, and system-level factors associated with CRC screening preferences, uptake, and follow-up; and (2) test the effectiveness of graded intensity MTsDNA intervention in the Alaska Native community setting. For the first aim, focus groups with Alaska Native people who are non- or inadequately adherent to CRC screening guidelines, and surveys and interviews with healthcare providers will be used to identify individual, interpersonal (provider), and health system factors for future intervention. For the second aim, a three-arm cluster randomized controlled trial (high intensity with patient navigation, medium intensity with mailed reminders, usual care) will provide evidence on the usefulness of MTsDNA in remote tribal communities as well as the first data on MT-sDNA diagnostic follow up adherence rates in the Alaska Native population. This aim will also provide evidence on the usability of MT-sDNA in the Alaska setting by evaluating MT-sDNA sample quality and neoplastic yield, which will inform plans to scale-up the intervention model. This project is innovative because an effective strategy for achieving higher screening rates than current practice could lead to increased prevention or early detection of CRC cases among Alaska Native people. The proposed research is significant because it will address a health disparity of community concern. This research has the potential to sustainably improve public health by increasing CRC screening rates among a rural/remote

Only 59% (29-73%) of Alaska Native people have been adequately screened for colorectal cancer (CRC), which could save lives, despite having the highest reported incidence of CRC in the world. A new at-home multi-target stool DNA screening test (MT-sDNA; Cologuard®) with high sensitivity for pre-cancerous polyps and CRC is now available. MT-sDNA has not been tested for feasibility or acceptability within the Alaska tribal health care delivery system, and it is unknown whether use of this new test will increase Alaska Native CRC screening rates. Our longterm goal is to improve screening and reduce CRC-attributable mortality. The objective of this application is to test the effectiveness of MT-sDNA for increasing CRC screening in Alaska Native communities using a mixed methods, community-based participatory research (CBPR) approach. The study will be conducted in collaboration with regional Tribal health organizations who are responsible for providing health care to geographically remote Alaska Native communities. This research has been requested by Tribal organizations. Although the proposed MT-sDNA has not been evaluated implementation strategy is eviden Our methods (in brief) in the tribal health setting or among rurar/ remove populations. Using the Soura Ecological Model, our research will be multi level, examining influence on nationts, providers, and tribal health organizations (THOs). This research study will pursue two specific aims: (1) Identify patient-, provider-, and system-level factors associated with CRC screening preferences, uptake, and follow-up; and (2) test the effectiveness of graded intensity MTsDNA intervention in the Alaska Native community setting. For the first aim, focus groups with Alaska Native people who are non- or inadequately adherent to CRC screening guidelines, and surveys and interviews with healthcare providers will be used to identify individual, interpersonal (provider), and health system factors for future intervention. For the second aim, a three-arm cluster randomized controlled trial (high intensity with patient navigation, medium intensity with mailed reminders, usual care) will provide evidence on the usefulness of MTsDNA in remote tribal communities as well as the first data on MT-sDNA diagnostic follow up adherence rates in the Alaska Native population. This aim will also provide evidence on the usability of MT-sDNA in the Alaska setting

the Alaska Native population. This aim will also provide evidence on the usability of MT-sDNA in the Alaska setting by evaluating MT-sDNA sample quality and neoplastic yield, which will inform plans to scale-up the intervention model. This project is innovative because an effective strategy for achieving higher screening rates than current practice could lead to increased prevention or early detection of CRC cases among Alaska Native people. The proposed research is significant because it will address a health disparity of community concern. This research has the potential to sustainably improve public health by increasing CRC screening rates among a rural/remote

Only 59% (29-73%) of Alaska Native people have been adequately screened for colorectal cancer (CRC), which could save lives, despite having the highest reported incidence of CRC in the world. A new at-home multi-target stool DNA screening test (MT-sDNA; Cologuard®) with high sensitivity for pre-cancerous polyps and CRC is now available. MT-sDNA has not been tested for feasibility or acceptability within the Alaska tribal health care delivery system, and it is unknown whether use of this new test will increase Alaska Native CRC screening rates. Our longterm goal is to improve screening and reduce CRC-attributable mortality. The objective of this application is to test the effectiveness of MT-sDNA for increasing CRC screening in Alaska Native communities using a mixed methods, community-based participatory research (CBPR) approach. The study will be conducted in collaboration with regional Tribal health organizations who are responsible for providing health care to geographically remote Alaska Native communities. This research has been requested by Tribal organizations. Although the proposed implementation strategy is evidence-informed and promising, it is novel in that MT-sDNA has not been evaluated in the tribal health setting or among rural/remote populations. Using the Social Ecological Model, our research will be multi-level, examining influence on patients, providers, and tribal health organizations (THOs). This research study will pursue two specific aims: (1) Identify patient-, provider-, and system-level factors associated with CRC screening preferences, uptake, and follow-up; and (2) test the effectiveness of graded intensity MTsDNA intervention in the Alaska Native community setting. For the first aim, focus groups with Alaska Native people who are non- or inadequately adherent to CRC screening guidelines, and surveys and interviews with healthcare providers will be used to identify individual, interpersonal (provider), and health system factors for future intervention. For the second aim, a three-arm cluster randomized controlled trial (high intensity with patient Why this is important dence on the userum as of the way of the stic follow up adherence rates in navigation, medium intensity with r sDNA in remote tribal communities the Alaska Native population. This aim will also provide evidence on the usability of MT_sDNA in the Alaska setting

by evaluating MT-sDNA sample quality and neoplastic yield, which will inform plans to scale-up the intervention model. This project is innovative because an effective strategy for achieving higher screening rates than current practice could lead to increased prevention or early detection of CRC cases among Alaska Native people. The proposed research is significant because it will address a health disparity of community concern. This research has the potential to sustainably improve public health by increasing CPC screening rates among a rural/remote

Introduction

Gives readers background information, rationale, context

Introduction: Problem statement

The major problem of interest and significance that your study will address



Introduction



Introduction: Objectives

What goals do you want your research to achieve?

Can be General/Specific Primary/Secondary



Do not make too many, or too ambitious

General objective:

To find new CRC screening methods for Alaska Native people

Specific objectives:

To identify factors associated with CRC screening preferences

To see if use of the stool DNA test will increase CRC screening among Alaska Native people

Introduction: Hypothesis

Tentative prediction of what you think you might find

For exploratory research, you may not have a hypothesis

Remember: you don't set out to prove your hypothesis, you set out to test it

People who are offered the stool DNA test will be more likely to complete screening than those offered just colonoscopy

High intensity navigation will lead to more people being screened than medium intensity or usual care

Methods

Arguably the most important section

Tells your audience how you will answer the research question



Methods: Research design

What study design will you use? Experimental Observational





For more information about study designs, see the Coursera Course" "Study Designs in Epidemiology"

Methods: Study participants

Who will your participants be? Inclusion/exclusion criteria Comparison group Sampling method

How do participants withdraw?

• Adults ages 45-75

THE R WE R

DELTA REGIONAL HOSPITAL

- No history of colorectal cancer
- Eligible for screening colonoscopy and stool DNA test



Methods: Intervention

What is the intervention? How will it be delivered? Who will it be delivered to? What's your control group?



Cluster Randomized Design



Methods: What will you measure?

Independent variables:

Exposure variables. The things you think might cause the outcome(s) of interest









Methods: What will you measure?

Dependent variables: The outcome(s) of interest

Methods: What will you measure?

"Background" variables: Other things that might affect the exposure or outcome











Considering context

How do the variables in your system fit together?





Methods: How will you measure it?







Your **Study instruments** should be included as an appendix

What will be your study process?

What will happen as part of your study?

Walk through the process, like a "dress rehearsal"



Photo courtesy of Bristol Bay Area Health Corporation



Methods: Sample size

How many participants do you need to test your hypothesis?



(A biostatistician can help with this, and many other things)

Methods: Data storage and security





Methods: Data analysis



Hint: your biostatistician should write this part!



Dissemination of results

Dissemination is a critical part of community-engaged research

Plan ahead how you will share results with participants, community members, and tribal health leaders



What is ANTHC doing about colorectal cancer among Alaska Native People?

Alsola Netro people have the tables of the second s

of lowering the age of first colorectal cancer screening to 40 in Alaska Native people

Abordo Nation people Asim higher meso of COL or people Asim higher meso of COL or people asim to be prevented to the people asim to be prevented as a second people as a second people as a second people abordone as a second people as a ANTTHE lass remains and the assessing pole as more second works of a second people abordone as a second people and people as a second people and an advance of the the people of PLD people and concrete the second PLD people and concrete the second PLD people and concrete the second people as a second people abordon the second people as a second people and the second people. In it fiber that reduces the the studi DNA test: sisk of color cancer? An initial appraisal

Alacka Taylor proper had Aglan Ironia of Daniertz Dennetic and Andresson in the ast these Advances also operated by the second field with the Advances filter and Danie was been miss of solar and filter and Danie was been miss of solar and filter and Danie was been miss of solar and filter and Danie was been miss of solar and the barlor and mission of the filter and the second mission of the filter and the second mission of the filter of the second solar and the filter and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the filter and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the barlor and the filter and the barlor and the barlor and the barlor and the barlor and the filter and the barlor and the barlo

Fecal Immunochemical testing for cancer screening among Alaska Native people

This study compared lines to pay of Chick ensuring tests in ETI fleed intermediated in the study of the study intermediated sectors and the study lines of the ETI or objects with the study of the stud

Ve People? the stual DNA test: An initial appraisal Environmengenetities types of CRC withouse tests tests types and the types of CRC withouse tests tests types and the types of CRC withouse tests test types and the types test types and the types types and types and types types

were denot som til Land Hanne Freeenne berane Talk Form, skich talle til eksen to Indraho Kappane skick för et satismåle recommanded sommaning som. Understandling sisk protective factors for colorectal cancer among

Alaska Native people Were not over if the better that these and present from, odowned even are earlier atoms Alaska Survey people to other people that have been marinal. This study will have been marinal allower the study will be been been been been been been used in the study allow be the study.

A new p to health for Ala: Native p

ARCART MAN

Many American file facility Statics groups breath scattering the file former search and the file increases the lackering on the Machington. The breatwork breath one field request are build search or contractions. Discussion of the file back of the search of the search of the back of the search of the search of the back of the search of the search of the back of the search of the search of the back of the search o

insurance pai

Incommon Weighter Incalify (constances in spacify).

Where can I

Information Vot estimate metart is your or eligible and get is



Conclusions

Give some expected outcomes

Reiterate how your proposed study will answer the research question and provide useful information to the world

What happens next? How will your research lead to more research or programs?

Ethics of a research proposal

Describe how the study will be conducted in accordance with relevant ethical guidelines

USA: Common Rule

Reviewing your research proposal in three questions

Is the proposed study adequate to answer the research question?

Is the research feasible?

Does the proposal provide enough detail that another investigator could do the study?

Lessons learned?

Iterative process

Gather your team early (and use them!)

Involve the community early and often

Think about the end at the beginning



https://cancercontrol.cancer.gov/is/funding/samplegrant-applications

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3282 423/

Coursera Courses:

Study Design in Epidemiology Understanding Clinical Research Statistical Inference



Thank You

qagaasakung baasee' tsin'aen quyanaq dogedinh quyanaa igamsiqanaghhalek 'awa'ahdah gunalchéesh chin'an mahsi' tsin'e e way dankoo háw'aa quyana

Diana Redwood, PhD, MPH | dredwood@anthc.org anthc.org/epicenter | (907) 729-4567 | anepicenter@anthc.org



ALASKA NATIVE TRIBAL HEALTH CONSORTIUM